KLN-1010

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameKLN-1010

Drug Alias NameKLN-1010

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionT lymphocyte replacementsAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesKelonia Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesKelonia Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsImmunoproliferative DisordersLymphoproliferative DisordersParaproteinemias +[7]

Inactive IndicationsImmune System DiseasesNeoplasms

Other Information

ATC CodeN/A